CA
NZ
UK
AU
IND
US
Aprea Therapeutics, Inc. (NASDAQ: APRE) disclosed an earnings per share (EPS) of $-0.22 for the quarter ending June 30, 2026, surpassing the consensus estimate of $-0.23. This indicates a reduction in the loss compared to expectations, which may resonate favorably with investors amid a …
Maze Therapeutics (NASDAQ: MAZE) posted cash and marketable securities of $494.9 million at June 30, 2026, a jump from $360.0 million at the end of 2025, lengthening its cash runway to 2029.
Abbott Laboratories reported fiscal Q2 2026 sales of $3.09 billion from its diagnostics segment, a noteworthy 42% increase that exceeded analyst expectations of $3.02 billion. The strong performance in diagnostics, particularly in cancer screening, underscores Abbott's effective growth strategy amid shifting market dynamics. In …
The infusion raised cash, cash equivalents and marketable securities to $201.1 million, up from $125.7 million three months earlier, and extends the firm’s operating runway well into the second half of 2028. The offering also lifted the company’s market cap to roughly $1.6 billion, …
Price $0.69 (±1.7% today) · Mkt cap $107M · Shares down 69.3% year-to-date · Next catalyst: not specified
GoodRx Holdings Inc (NASDAQ: GDRX). has launched a series of subscription plans aimed at improving consumer healthcare access and strengthening market engagement. The recent launch is part of a strategic push to provide value amid rising competition in the healthcare sector, particularly among digital …
Hims & Hers Health, Inc. announced its Q2 2026 results, revealing revenue of $753.2 million, up 38% from a year prior. Despite this commendable growth figure, the company'sEarningsnarrative appears more complicated due to significant margin compression. Analysts are paying close attention to these developments, …
Humacyte, Inc. raised gross proceeds of $57.5 million through a public offering in June and reported second quarter sales of $0.4 million for its Symvess product. These results follow significant advancements inClinical Trialsthat position Humacyte as a leader in innovative dialysis access solutions. Investors …
Market capitalization sits at roughly $325 million, while the 52‑week price band stretches from $1.33 to $2.53. The result validates investor optimism surrounding the company’s PAH program and fuels further price momentum.
LENZ Therapeutics reported a Q2 loss but managed to exceed revenue expectations, beating estimates by $0.05 per share. The company's performance has sparked a substantial rally in its stock, as heightened investor sentiment reflects confidence in its growth trajectory. The market's positive reception illustrates …
Please wait processing your request...